Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Mydecine Innovations Group Inc (OP: MYCOF )

0.0793 +0.0011 (+1.41%)
Streaming Delayed Price Updated: 9:30 AM EST, Dec 5, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Mydecine Innovations Group Inc

< Previous 1 2 3 4 Next >
InvestorNewsBreaks – Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) Updates Special Access Program
Via Investor Brand Network
Topics Artificial Intelligence
Exposures Artificial Intelligence Product Safety
InvestorNewsBreaks – Mydecine Innovations Group Inc. (CSE: MYCO) (AQSE: MYIG) (OTC: MYCOF) Files Prospectus Supplement, Closes Share Subscription Agreements
Via Investor Brand Network
Topics Artificial Intelligence
Exposures Artificial Intelligence Product Safety
InvestorNewsBreaks – Mydecine Innovations Group Inc. (CSE: MYCO) (AQSE: MYIG) (OTC: MYCOF) Reports on Company Progress in Q4 2023 Update
Via Investor Brand Network
Exposures Product Safety
Mydecine Provides Q4 2023 Business Update
From Mydecine Innovations Group Inc.
Via GlobeNewswire
Mydecine Innovations Group gearing up for human trials after completing Aquis listing
Mydecine Innovations Group Inc (OTC:MYCOF, NEO:MYCO) CEO Joshua Bartch speaks to Thomas Warner from Proactive London about the biotechnology company's ambitious goals in the psychedelic medicine... 
Via TheNewswire.com
InvestorNewsBreaks – Mydecine Innovations Group Inc. (CSE: MYCO) (AQSE: MYIG) (OTC: MYCOF) Starts Trading on the AQSE Growth Market
Via Investor Brand Network
Topics Artificial Intelligence Intellectual Property
Exposures Artificial Intelligence Intellectual Property Product Safety
Mydecine Innovations Group Announces Admission to Trading on the AQSE Growth Market in London, UK and First Day of Dealings
From Mydecine Innovations Group Inc.
Via GlobeNewswire
InvestorNewsBreaks – Mydecine Innovations Group Inc. (CSE: MYCO) (OTC: MYCOF) (FSE: 0NFA) Common Shares Begin Listing on CSE
Via Investor Brand Network
Topics Artificial Intelligence
Exposures Artificial Intelligence Product Safety
InvestorNewsBreaks – Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) Expects UK Dual Listing Admission Next Month
Via Investor Brand Network
Topics Artificial Intelligence
Exposures Artificial Intelligence Product Safety
InvestorNewsBreaks – Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) Receives CSE Listing Conditional Approval
Via Investor Brand Network
Topics Artificial Intelligence
Exposures Artificial Intelligence Product Safety
Mydecine Announces Conditional Approval of CSE Listing
From Mydecine Innovations Group Inc.
Via GlobeNewswire
InvestorNewsBreaks – Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) Announces Leadership Update
Via Investor Brand Network
InvestorNewsBreaks – Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) Reports on Special Meeting
Via Investor Brand Network
Topics Artificial Intelligence
Exposures Artificial Intelligence Product Safety
InvestorNewsBreaks – Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) Files Prospectus Supplement, Closes 1st Tranche of Subscription Agreement, Reappoints Board Member
Via Investor Brand Network
Mydecine Innovations Group Files Prospectus Supplement, Announces Closing Under Share Subscription Agreement and Provides Update on Its Board of Directors
From Mydecine Innovations Group Inc.
Via GlobeNewswire
InvestorNewsBreaks – Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) Announces Results of Annual General Shareholders Meeting
Via Investor Brand Network
Topics Artificial Intelligence
Exposures Artificial Intelligence Product Safety
Mydecine Reports its 2023 Annual General Shareholders' Meeting Results
From Mydecine Innovations Group Inc.
Via GlobeNewswire
InvestorNewsBreaks – Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) Announces Positive Preclinical Results on MYCO-006 Series
Via Investor Brand Network
Topics Artificial Intelligence Intellectual Property
Exposures Artificial Intelligence Intellectual Property Product Safety
Mydecine Reports Positive Preclinical Results on the MYCO-006 Series of its Short-Acting MDMA Analogues
From Mydecine Innovations Group Inc.
Via GlobeNewswire
InvestorNewsBreaks – Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) Closes on Share Subscription Agreement
Via Investor Brand Network
InvestorNewsBreaks – Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) Announces Filing of Prospectus Supplement, First Tranche Closing
Via Investor Brand Network
InvestorNewsBreaks – Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) Issues Corporate Update
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property
Mydecine Innovations Group Provides Corporate Update
From Mydecine Innovations Group Inc.
Via GlobeNewswire
Mydecine Reports Financial Results for the Year Ended December 2022
From Mydecine Innovations Group Inc.
Via GlobeNewswire
BioMedNewsBreaks – Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) Reports on Debt Settlement Agreements
Via Investor Brand Network
InvestorNewsBreaks – Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) Closes Sale of Mindleap Health Inc.
Via Investor Brand Network
Mydecine Innovations Group Closes Sale of Its Wholly-Owned Subsidiary, Mindleap Health Inc.
From Mydecine Innovations Group Inc.
Via GlobeNewswire
InvestorNewsBreaks – Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) Announces Filing of Prospectus Supplement, Closing Under Share Subscription Agreement
Via Investor Brand Network
InvestorNewsBreaks – Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) Announces Filing of Prospectus Supplement, Closes Share Subscription Agreement
Via Investor Brand Network
Mydecine Reports Financial Results for the Third Quarter of Fiscal Year 2022
From Mydecine Innovations Group Inc.
Via GlobeNewswire
< Previous 1 2 3 4 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.